MC2R Antagonist Compounds for Selective Cortisol Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions related to excessive glucocorticoid levels, such as Cushing's syndrome and congenital adrenal hyperplasia, often induce unwanted side effects due to the accumulation of other steroid products, and there is a need for selective modulation of the melanocortin 2 receptor (MC2R) to address these conditions effectively.
Innovation Solution
Development of compounds that act as MC2R modulators, specifically MC2R antagonists, to regulate cortisol synthesis and secretion, thereby treating conditions like Cushing's syndrome, ectopic ACTH syndrome, congenital adrenal hyperplasia, depressive illness, and septic shock with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current treatments for excessive glucocorticoid levels are used, then glucocorticoid levels are reduced, but unwanted side effects occur due to accumulation of other steroid products
Solution Approach 1:
The invention segments the treatment approach by developing compounds that selectively target only the MC2R receptor, thereby isolating the therapeutic effect to cortisol regulation while leaving other steroid pathways unaffected. This receptor-specific segmentation eliminates the side effects caused by non-selective steroid accumulation.
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular structures (Formula I and Formula II) that exhibit high affinity and selectivity for the MC2R receptor binding site. The local molecular characteristics of these compounds enable them to interact specifically with MC2R while avoiding other steroid receptors, thus treating glucocorticoid excess without causing unwanted steroid accumulation.
2Reliability
If selective MC2R modulation is implemented, then cortisol production is specifically inhibited, but development of selective compounds requires complex molecular design
Solution Approach 1:
The invention utilizes parameter changes by systematically modifying molecular parameters in Formula I and Formula II, including substituent groups (R1-R10), ring structures, and linker variations. By adjusting these molecular parameters, the invention optimizes both the selectivity for MC2R and the pharmacological properties of the compounds, achieving reliable selective treatment through controlled molecular design.
Solution Approach 2:
The invention employs composite molecular structures combining multiple functional moieties in Formula I and Formula II, including aromatic rings, heterocyclic groups, and specific substituent patterns. These composite molecular architectures work synergistically to achieve high MC2R selectivity while managing the inherent complexity through structured molecular assembly.
Data Source
AI summary
Described herein are compounds that are melanocortin subtype-2 receptor (MC2R) modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of MC2R activity.